Logo image of IBIO

IBIO INC (IBIO) Stock Fundamental Analysis

NASDAQ:IBIO - Nasdaq - US4510337086 - Common Stock - Currency: USD

0.9281  -0.1 (-9.89%)

After market: 0.9294 +0 (+0.14%)

Fundamental Rating

2

Taking everything into account, IBIO scores 2 out of 10 in our fundamental rating. IBIO was compared to 559 industry peers in the Biotechnology industry. IBIO scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. IBIO does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year IBIO has reported negative net income.
In the past year IBIO has reported a negative cash flow from operations.
In the past 5 years IBIO always reported negative net income.
IBIO had a negative operating cash flow in each of the past 5 years.
IBIO Yearly Net Income VS EBIT VS OCF VS FCFIBIO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

IBIO's Return On Assets of -109.89% is on the low side compared to the rest of the industry. IBIO is outperformed by 79.07% of its industry peers.
With a Return On Equity value of -184.45%, IBIO is not doing good in the industry: 66.19% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -109.89%
ROE -184.45%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
IBIO Yearly ROA, ROE, ROICIBIO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for IBIO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IBIO Yearly Profit, Operating, Gross MarginsIBIO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K -10K

More info and screens

5

2. Health

2.1 Basic Checks

IBIO does not have a ROIC to compare to the WACC, probably because it is not profitable.
IBIO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
IBIO Yearly Shares OutstandingIBIO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 200K 400K 600K 800K
IBIO Yearly Total Debt VS Total AssetsIBIO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M

2.2 Solvency

Based on the Altman-Z score of -25.62, we must say that IBIO is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of IBIO (-25.62) is worse than 87.66% of its industry peers.
There is no outstanding debt for IBIO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -25.62
ROIC/WACCN/A
WACC13.64%
IBIO Yearly LT Debt VS Equity VS FCFIBIO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

A Current Ratio of 1.12 indicates that IBIO should not have too much problems paying its short term obligations.
IBIO has a Current ratio of 1.12. This is amonst the worse of the industry: IBIO underperforms 86.05% of its industry peers.
A Quick Ratio of 1.12 indicates that IBIO should not have too much problems paying its short term obligations.
The Quick ratio of IBIO (1.12) is worse than 85.33% of its industry peers.
Industry RankSector Rank
Current Ratio 1.12
Quick Ratio 1.12
IBIO Yearly Current Assets VS Current LiabilitesIBIO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

More info and screens

3

3. Growth

3.1 Past

IBIO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 86.33%, which is quite impressive.
The Revenue has grown by 650.00% in the past year. This is a very strong growth!
IBIO shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -35.53% yearly.
EPS 1Y (TTM)86.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%30.99%
Revenue 1Y (TTM)650%
Revenue growth 3Y-54.38%
Revenue growth 5Y-35.53%
Sales Q2Q%N/A

3.2 Future

IBIO is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.67% yearly.
Based on estimates for the next years, IBIO will show a very negative growth in Revenue. The Revenue will decrease by -14.87% on average per year.
EPS Next Y78.54%
EPS Next 2Y34.7%
EPS Next 3Y24.06%
EPS Next 5Y13.67%
Revenue Next Year1100%
Revenue Next 2Y226.6%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
IBIO Yearly Revenue VS EstimatesIBIO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2031 2032 10M 20M 30M
IBIO Yearly EPS VS EstimatesIBIO Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 -100 -200 -300

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for IBIO. In the last year negative earnings were reported.
Also next year IBIO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IBIO Price Earnings VS Forward Price EarningsIBIO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IBIO Per share dataIBIO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2

4.3 Compensation for Growth

IBIO's earnings are expected to grow with 24.06% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y34.7%
EPS Next 3Y24.06%

More info and screens

0

5. Dividend

5.1 Amount

IBIO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

IBIO INC

NASDAQ:IBIO (6/13/2025, 8:08:42 PM)

After market: 0.9294 +0 (+0.14%)

0.9281

-0.1 (-9.89%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-02 2025-05-02/bmo
Earnings (Next)09-18 2025-09-18/amc
Inst Owners15.78%
Inst Owner Change-0.97%
Ins Owners4.64%
Ins Owner Change0.54%
Market Cap15.33M
Analysts82.22
Price Target4.9 (427.96%)
Short Float %4.17%
Short Ratio0.52
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-26.21%
Min EPS beat(2)-50.12%
Max EPS beat(2)-2.3%
EPS beat(4)1
Avg EPS beat(4)-33.84%
Min EPS beat(4)-88.99%
Max EPS beat(4)6.05%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-1.37%
PT rev (3m)-1.37%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 40.89
P/FCF N/A
P/OCF N/A
P/B 1.35
P/tB 2.9
EV/EBITDA N/A
EPS(TTM)-2.34
EYN/A
EPS(NY)-1.4
Fwd EYN/A
FCF(TTM)-0.95
FCFYN/A
OCF(TTM)-0.94
OCFYN/A
SpS0.02
BVpS0.69
TBVpS0.32
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -109.89%
ROE -184.45%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.12
Quick Ratio 1.12
Altman-Z -25.62
F-Score4
WACC13.64%
ROIC/WACCN/A
Cap/Depr(3y)332.24%
Cap/Depr(5y)252.44%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)86.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%30.99%
EPS Next Y78.54%
EPS Next 2Y34.7%
EPS Next 3Y24.06%
EPS Next 5Y13.67%
Revenue 1Y (TTM)650%
Revenue growth 3Y-54.38%
Revenue growth 5Y-35.53%
Sales Q2Q%N/A
Revenue Next Year1100%
Revenue Next 2Y226.6%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%
EBIT growth 1Y-41.38%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y65.96%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y57.96%
OCF growth 3YN/A
OCF growth 5YN/A